Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies

Recruiting

• Conditions: Lymphoma

• Registration Number: NCT05275036
• Lead Sponsor: Sun Yat-sen University

Brief Summary

ASCEND-LYM is a prospective, multi-center, observational study aimed at detecting early stage lymphoma and constrcuting prognostic model by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 493 participants including lymphoid malignancies and benign diseases.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-02-28
• Study First Submitted QC: 2022-03-09
• Study First Posted: 2022-03-11
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-06
• Last Update Posted: 2022-04-14
• Study Start: 2022-05-31
• Primary Completion: 2023-06-30
• Study Completion: 2025-08-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 493

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The sensitivity and specificity of early detection model for lymphoma based on cfDNA methylation or combined with other biomarkers.	12 months

Secondary Outcome Measures

Name	Time	Method
The sensitivity and specificity of the optimal model in lymphoma patients at different clinical stages.	12 months
The sensitivity and specificity of the optimal model in different subtypes of lymphoma patients.	12 months
The rate of high-risk patients found by prognostic model for lymphoma based on cfDNA methylation or combined with other biomarkers.	24 months

Trial Locations

Locations (1)

SunYat-sen university cancer center; 🇨🇳 Guangzhou, China